The cannabinoid receptor‐1 antagonist rimonabant inhibits platelet activation and reduces pro‐inflammatory chemokines and leukocytes in Zucker rats

Abstract

We demonstrate positive modulation of circulating neutrophil and monocyte numbers, reduced platelet activation and lower RANTES and MCP-1 levels by rimonabant in Zucker rats. This may potentially contribute to a reduction of cardiovascular risk.